Month: November 2021

Nov 03 2021

Uncategorized

Schizophrenia burden totaled more than $340 billion in 2019

by Clinical Editor

No Comments

Schizophrenia’s approximate societal burden was $341.5 billion in the U.S. in 2019, according to study results presented at Psych Congress.Adjusted for inflation, this represented a 99.8% increase in …

Nov 03 2021

Uncategorized

COVID Doesn’t Dampen LAI Antipsychotic Prescribing in Schizophrenia

by Clinical Editor

No Comments

Of the prescribers who responded to the survey, 59.8% said that they did not see any increases or decreases in their 2020 prescribing trends. Among this majority, most concerns about...

Nov 03 2021

Uncategorized

Healthcare Providers Weigh In on Adjunctive Digital Schizophrenia Therapy

by Clinical Editor

No Comments

Psychiatrists and psychologists were surveyed about their expectations for an adjunctive digital therapeutic created to treat schizophrenia.

Nov 03 2021

Uncategorized

Teva’s Risperidone Injectable Wards Off Schizophrenia Relapse in Phase III

by Clinical Editor

No Comments

Teva Pharmaceutical announced positive results from the company’s Phase III trial on a subcutaneous, long-acting injectable risperidone formulation in the treatment of schizophrenia.

Nov 02 2021

Uncategorized

Is Earlier Use of Long-Acting Injectable Drugs for Schizophrenia Better?

by Clinical Editor

No Comments

For Medicaid beneficiaries with schizophrenia, early initiation of long-acting injectable antipsychotics (LAIs) was associated with fewer inpatient stays and emergency room (ER) visits compared with …

Nov 02 2021

Uncategorized

COVID Doesn’t Dampen LAI Antipsychotic Prescribing in Schizophrenia

by Clinical Editor

No Comments

Of the prescribers who responded to the survey, 59.8% said that they did not see any increases or decreases in their 2020 prescribing trends. Among this majority, most concerns about...

Nov 02 2021

Uncategorized

ATAI Life’s Schizophrenia Candidate Shows Promising Action In Mid-Stage Study

by Clinical Editor

No Comments

ATAI Life Sciences NV (NASDAQ: ATAI) announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS). Related Link:...

Nov 02 2021

Uncategorized

Teva’s Risperidone Injectable Wards Off Schizophrenia Relapse in Phase III

by Clinical Editor

No Comments

Teva Pharmaceutical announced positive results from the company’s Phase III trial on a subcutaneous, long-acting injectable risperidone formulation in the treatment of schizophrenia.

Nov 02 2021

Uncategorized

‘Taking Control of Schizophrenia’ Addresses Common Concerns and Provides Critical Information for Those Navigating Mental Illness

by Clinical Editor

No Comments

Lightstone has released “Taking Control of Schizophrenia: My Story,” a comprehensive and holistic guide to living with schizophrenia and other mental illnesses. Drawing from both his experiences …

Nov 01 2021

Uncategorized

Antipsychotic Patch Quiets Schizophrenia-Related Hostility

by Clinical Editor

No Comments

The antipsychotic “patch” effectively reduced hostility among patients with schizophrenia, a researcher reported. In a post-hoc analysis of a phase III trial, once-daily asenapine transdermal system …